Moderna's Revenue Decline May Be Slowing, But Analyst Uncertainty Lingers Around Execution

Moderna Inc (MRNA) reports second-quarter 2026 earnings before the market opens on Friday, July 31st, with analysts expecting a loss of $1.97 per share. The biotech company has consistently beaten estimates over the past four quarters, but investors will be watching closely to see if the company can maintain momentum as it navigates the post-pandemic landscape and advances its pipeline beyond COVID-19 vaccines. With the stock trading at $57.92 and options pricing a 6.49% expected move, this report could provide critical insight into whether Moderna's diversification strategy is gaining traction.

Part 1: Earnings Preview

Moderna Inc is a biotechnology company that develops messenger RNA (mRNA) medicines, with a portfolio spanning respiratory vaccines (including COVID-19, RSV, and seasonal influenza), oncology therapeutics, rare disease treatments, and latent virus vaccines. The company operates globally across the United States, Europe, and international markets, with strategic collaborations including partnerships with Merck.

Moderna is scheduled to report Q2 2026 earnings before the market opens on Friday, July 31st. Analysts expect the company to post a loss of $1.97 per share on revenue of approximately $102.93 million, according to consensus estimates from 8 analysts. The most recently reported quarter (Q1 2026) delivered a loss of $1.18 per share, which significantly beat the consensus estimate of $3.02 by 60.93%.

Comparing to the same quarter last year, the expected loss of $1.97 per share represents a 7.51% improvement from the $2.13 loss reported in Q2 2025, suggesting analysts anticipate continued progress in narrowing losses as the company transitions its business model.

Three key themes define this earnings story:

Post-Pandemic Revenue Transition: Moderna faces the critical challenge of demonstrating sustainable revenue growth beyond COVID-19 vaccines. The company reported $389 million in revenue last quarter—up 260.2% year-over-year—but investors will scrutinize whether this momentum can continue and what portion comes from diversified product lines versus legacy COVID products.

Pipeline Progress and Diversification: With programs spanning oncology (including intismeran autogene and cancer antigen therapy), rare diseases (propionic and methylmalonic acidemia, cystic fibrosis), and additional respiratory vaccines (CMV, EBV, HIV, norovirus, Zika, Nipah, Mpox, and Lyme disease), investors are watching for clinical milestones and regulatory progress that could validate the company's long-term growth thesis beyond its COVID franchise.

Profitability Path and Cost Management: With consensus estimates projecting a full-year 2026 loss of $6.41 per share (improving to $4.33 in 2027), the market is focused on management's ability to control operating expenses while investing in R&D, and any updated guidance on the timeline to profitability.

Analyst commentary heading into the release reflects cautious positioning. Goldman Sachs recently raised its price target from $49 to $67 while maintaining a "neutral" rating, while Royal Bank of Canada lifted its target from $38 to $45 with a "sector perform" rating. However, Bank of America remains bearish with an "underperform" rating and $38 price target. The consensus among 23 analysts shows a "Hold" rating (2.96 on a 5-point scale), with price targets ranging from $25 to $135 and a mean target of $51.95—suggesting limited upside from current levels.

Part 2: Historical Earnings Performance

Moderna has established a strong pattern of beating earnings estimates over the past four quarters, consistently outperforming analyst expectations by substantial margins.

In Q1 2026 (March), the company reported a loss of $1.18 per share versus the $3.02 consensus estimate, delivering a 60.93% beat. The prior quarter (Q4 2025, December) saw a loss of $2.11 against expectations of $2.60, a 18.85% beat. Q3 2025 (September) produced the most impressive outperformance with a loss of just $0.51 compared to the $2.15 estimate—a 76.28% beat. Even Q2 2025 (June) delivered a 28.76% beat with a $2.13 loss versus the $2.99 consensus.

This consistent pattern of significant beats—averaging well over 40% across the four quarters—suggests either persistent analyst conservatism in modeling the business or genuine operational outperformance as Moderna navigates its transition. The trend shows improving fundamentals, with reported losses narrowing from $2.13 four quarters ago to $1.18 most recently, indicating progress toward the company's profitability goals.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Moderna typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action around Moderna's earnings releases shows significant volatility, with the stock averaging an absolute move of 6.13% on Day 0 and 4.34% on Day +1. The Day 0 trading range averages 9.18%, while Day +1 sees an average range of 7.43%, indicating sustained volatility into the second session.

The most recent earnings release (May 1, 2026) saw a modest 1.24% decline on Day 0 with a 10.27% intraday range, followed by a 4.25% gain on Day +1. The February 2026 report triggered a 5.29% Day 0 gain and 4.03% Day +1 gain, both with substantial intraday ranges exceeding 7%. However, the August 2024 report stands out as an extreme outlier, with a devastating 21.01% Day 0 decline—likely reflecting a significant fundamental disappointment or guidance cut that skews the historical averages.

Excluding that outlier, the pattern suggests investors should expect Day 0 moves in the 3-6% range with potential for follow-through on Day +1, particularly if the company delivers another substantial earnings beat or provides encouraging pipeline updates.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 6.49% for this earnings release, which aligns closely with the 6.13% average absolute Day 0 move from recent history. This suggests options traders are anticipating typical volatility rather than an outsized reaction, despite the stock's history of significant earnings beats.

Part 3: What Analysts Are Saying

The analyst community maintains a cautious stance on Moderna, with a consensus rating of 2.96 (Hold) based on 23 analysts. The breakdown shows 2 Strong Buy ratings, 18 Hold ratings, 1 Moderate Sell, and 2 Strong Sell ratings—reflecting a predominantly neutral-to-skeptical view despite the company's recent operational improvements.

The average price target of $51.95 implies 10.3% downside from the current price of $57.92, with estimates ranging from a low of $25.00 to a high of $135.00. This wide dispersion reflects significant disagreement about the company's long-term value, with bears questioning the sustainability of revenue post-COVID and bulls betting on pipeline success.

Sentiment has improved over the past month, with one analyst upgrading from Strong Sell to Moderate Sell. However, the overall tone remains defensive, as the consensus target sitting below the current price suggests analysts believe the stock has run ahead of fundamentals. Recent target increases from Goldman Sachs (to $67) and Royal Bank of Canada (to $45) acknowledge improving near-term performance but stop short of bullish recommendations, maintaining neutral ratings that reflect wait-and-see positioning on the company's diversification efforts.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 56% Buy signal, down from 64% last week and 100% last month, indicating deteriorating technical momentum heading into the earnings release. This weakening signal suggests the stock has lost some of its bullish conviction despite trading above key long-term moving averages.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-slightly-bullish signal indicates near-term momentum has stalled after recent weakness
• Medium-term (50% Buy): Neutral reading suggests the stock is consolidating in the intermediate timeframe without clear directional bias
• Long-term (100% Buy): Strong buy signal reflects positive positioning in the longer-term trend, supported by the stock's position well above its 200-day moving average

Trend Characteristics: The combination of Average strength and Average direction suggests Moderna is in a neutral trend environment heading into earnings, lacking the strong momentum that would typically support a bullish breakout but also not showing signs of technical breakdown.

At $57.92, the stock trades above its 5-day ($55.58), 10-day ($57.40), 100-day ($54.74), and 200-day ($44.72) moving averages, but has fallen below its 20-day ($64.99) and 50-day ($58.22) averages.

The recent breakdown below the 20-day and 50-day moving averages after trading as high as $85.60 in the 52-week range signals a loss of near-term momentum. The stock's position above longer-term averages provides some technical support, but the weakening Barchart Opinion and proximity to the 50-day average at $58.22 suggests limited cushion if earnings disappoint. The technical setup is cautiously neutral—supportive enough that a strong beat could trigger a rally back toward the $65 level, but vulnerable to a test of the $54-55 support zone if results or guidance fall short of expectations.